Semaglutide

$79.00

Size

In stock
COA-verified
≥99% purity.
USA manufactured.
In stock
COA-verified
≥99% purity.
USA manufactured.
COA-verified
In stock
≥99% purity.
USA manufactured.
In stock
≥99% purity.
USA manufactured.
In stock
≥99% purity.
USA manufactured.
In stock
≥99% purity.
USA manufactured.

What Is Semaglutide?

Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), modified with a C18 fatty acid chain conjugation to enable albumin binding and extend half-life. In research settings, Semaglutide is studied for its interactions with GLP-1 receptors in pancreatic, hypothalamic, hepatic, and peripheral tissue models.

BioRhex supplies Semaglutide as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.

Semaglutide is a GLP-1 receptor agonist studied for its metabolic signaling properties across multiple tissue models. In vitro and preclinical research examines how Semaglutide may influence:

• GLP-1 receptor binding and cAMP accumulation signaling in pancreatic models
• Insulin secretion and glucagon suppression pathway interactions
• Hypothalamic energy homeostasis and appetite pathway signaling
• Hepatic lipid metabolism and gluconeogenesis pathway modeling
• Cardiovascular and endothelial GLP-1 receptor pathway interactions
All findings referenced are from controlled research environments and do not represent clinical outcomes or therapeutic claims.

Semaglutide was developed as part of Novo Nordisk’s GLP-1 analogue research program, designed to extend the half-life of GLP-1 from minutes to approximately one week through structural modifications including amino acid substitutions and fatty acid conjugation.

Research into GLP-1 receptor agonists grew significantly following earlier preclinical work characterizing the metabolic regulatory role of incretin hormones. Semaglutide’s extended activity window made it a practical research tool for studying chronic GLP-1 axis modulation.

It remains one of the most studied GLP-1 analogues in metabolic pathway and incretin biology research within laboratory settings.

Reserch-grade coenzyme compound visualization.

COMPOUND

HXEGTFTSDVSSYLEGQAAKEFIAWLVRGRG

TYPE

GLP-1 receptor agonist

MOLECULAR FORMULA

C₁₈₇H₂₉₁N₄₅O₅₉

MOLECULAR WEIGHT

4113.58 g/mol

PURITY

≥99%

ANALYSIS

HPLC Verified

STORAGE

Store at -20°C. Protect from light and moisture.

CLASSIFICATION

Reserch Use Only

Research Findings

Published and preclinical research on Semaglutide covers several areas of scientific investigation, including:

GLP-1 receptor pharmacology: Studies examine Semaglutide’s receptor binding kinetics, cAMP accumulation, and downstream insulin secretion signaling in pancreatic cell models.
Appetite and energy pathway research: Research explores GLP-1R activation in hypothalamic circuits associated with energy intake regulation in preclinical models.
Hepatic metabolic signaling: Laboratory models investigate Semaglutide’s interactions with liver metabolic pathways including lipogenesis and gluconeogenesis.
Cardiovascular pathway research: Studies evaluate GLP-1R agonism effects on cardiac and endothelial signaling in experimental systems.

All findings referenced are from controlled, non-clinical research models and do not imply therapeutic or clinical application.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

2. Marso SP, Bain SC, Consoli A, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine, 375(19), 1834–1844. https://doi.org/10.1056/NEJMoa1607141

3. Davies M, Færch L, Jeppesen OK, et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0

4. Kushner RF, Calanna S, Davies M, et al. (2020). Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity, 28(6), 1050–1061. https://doi.org/10.1002/oby.22794

FAQ

What type of research is Semaglutide used for?

Semaglutide is used in laboratory research settings. All supplied compounds are intended strictly for in vitro and preclinical research purposes. Use is limited to controlled scientific environments.

Where is BioRhex’s Semaglutide manufactured?

All BioRhex compounds, including Semaglutide, are manufactured in a GMP-compliant facility located in the United States.

What testing does BioRhex conduct on Semaglutide?

Every batch of Semaglutide undergoes third-party HPLC purity testing, mass spectrometry identity verification, and sterility testing. A Certificate of Analysis is included with every order, documenting batch-specific purity data at a ≥99% threshold.

Is Semaglutide approved for human use?

No. Semaglutide is not FDA-approved and is not intended for human or animal administration. It is supplied exclusively for laboratory research purposes.

Who should handle this compound?

Only qualified personnel in controlled laboratory settings following appropriate safety and handling protocols.

All BioRhex compounds are supplied strictly for laboratory research purposes. Not for human or animal consumption, medical use, or therapeutic application. Semaglutide is not FDA-approved for any medical purpose. Nothing on this page should be interpreted as health guidance or applied outside controlled research settings.